rational therapeutics .

The response against NSCLC in the only NSCLC patient in the trial was not such a surprise . A few years back Rational Therapeutics of L.A. independently tested SBP002 on NSCLC . Nice to see the first verification of his results .

<
SBP002 44%
CDDP/Gem 22%
5Fu/Nav 11%
5Fu/Gem 11%
Carbo/Tax 11%
MMC/5Fu 11%
5Fu/CDDP 11%
Gem/Topo/CDDP 11%
Nav 11% >>

When you consider that these tests were done on fresh tumour human samples ex-vivo , without the extra advantage provided by the now proven immune system boost , the results are extraordinary .
I believe Rational Therapeutics are currently conducting further tests to refine which cancers are the best targets for ongoing Phase 2 trials .
Cheers